27 October 2022 | Other

Merck CEO will take charge of the company’s chairman

On Wednesday, the company Merck & Co announced that Ken Frazier leaves the post of chairman. He will be replaced by Chief Executive Officer Rob Davis, who has taken on extra responsibilities on December 1.

Frazier joined the company nearly 30 years ago, and over the years, he was helping the company to stay among the leaders in the drug production field.

He was steering the company during the difficult lawsuit related to the painkiller Vioxx, which was withdrawn from the market. He also played a pivotal role in the acquisition of US drug product manufacturer Schering-Plough. In 2009 the company received the possibility to sell the drug Keytruda. Then, this drug became Merck's best-selling product. 



Company MarketCheese
Period: 30.06.2026 Expectation: 3300 pips
Buying USDCAD up to 1.41500
10 April 2026 32
Period: 17.04.2026 Expectation: 700 pips
AUDCAD is at risk of correction amid fragile Middle East truce
10 April 2026 30
Gold buy
Period: 30.04.2026 Expectation: 800 pips
Invest in gold once $4,800 gives way
10 April 2026 56
Brent sell
Period: 17.04.2026 Expectation: 630 pips
Brent crude sell-off targets $92.5
10 April 2026 30
Period: 17.04.2026 Expectation: 920 pips
Friday profit-taking puts GBPUSD buyers on sidelines
10 April 2026 30
Period: 30.06.2026 Expectation: 3000 pips
Buying USDJPY up to 162.00
09 April 2026 66
Go to forecasts